Tesamorelin Results Timeline
What the standard Tesamorelin research protocol looks like phase by phase, over a typical 12–26 weeks (up to 52 with monitoring) cycle. This is the escalation schedule from our full dosing protocol, presented as a timeline rather than a table.
Compare:Tesamorelin vs MOTS-c →
Quick Facts
FREQUENCYOnce daily (evening preferred)
CYCLE LENGTH12–26 weeks (up to 52 with monitoring)
DOSE RANGE1–2 mg/day
ROUTESubcutaneous injection
Phase-by-Phase Timeline
Loading / Titration
Week 1
Target dose: 1 mg / 1000 mcg
Maintenance
Weeks 2–12+
Target dose: 2 mg / 2000 mcg
Reported in Research
- ✓12–26 weeks; clinical trials support up to 52 weeks with monitoring.
This timeline reflects the structure of the standard Tesamorelin research protocol documented on this site — it is not a guarantee of individual outcomes, and timelines vary between research subjects. All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.